

Product datasheet for TL311612V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

MAGEA4 Human shRNA Lentiviral Particle (Locus ID 4103)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: MAGEA4 Human shRNA Lentiviral Particle (Locus ID 4103)

Locus ID: 4103

Synonyms: CT1.4; MAGE-41; MAGE-X2; MAGE4; MAGE4A; MAGE4B

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: MAGEA4 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1

scramble control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001011548, NM 001011549, NM 001011550, NM 002362, NM 001011549.1,

NM 001011548.1, NM 002362.1, NM 002362.2, NM 002362.3, NM 002362.4, NM 001011550.1, BC017723, BC017723.1, BC096712, BM548926, BM562570

UniProt ID: P43358

Summary: This gene is a member of the MAGEA gene family. The members of this family encode

proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita. Several variants encoding the

same protein have been found for this gene. [provided by RefSeq, Aug 2020]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our custom shRNA service.





MAGEA4 Human shRNA Lentiviral Particle (Locus ID 4103) - TL311612V

Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).